Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis
- 1 January 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 482 (4) , 1430-1436
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
- Scientific Research in Japan
- Chugai Pharmaceutical Co. Ltd
This publication has 32 references indexed in Scilit:
- Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older menAmerican Journal of Physiology-Endocrinology and Metabolism, 2015
- Management of Postmenopausal OsteoporosisAnnual Review of Medicine, 2015
- Prevalence of osteoporosis in prostate cancer survivors: a meta-analysisEndocrine, 2013
- Osteoporosis in menNature Reviews Endocrinology, 2013
- Testicular function and bone metabolism—beyond testosteroneNature Reviews Endocrinology, 2013
- Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability studyJournal of Bone and Mineral Metabolism, 2009
- Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in OsteoclastsCell, 2007
- Activities of daily living decrease similarly in hospital-treated patients with a hip fracture or a vertebral fracture: a one-year prospective study in 151 patientsScandinavian Journal of Public Health, 2004
- Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent FracturesArchives of internal medicine (1960), 2004
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001